Itacitinib before CAR T for aggressive B-cell lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests itacitinib given before CAR T cell therapy to see if it can improve outcomes for people with diffuse large B-cell lymphoma (DLBCL). It may help by calming certain immune signals before CAR T is started.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have confirmed diffuse large B-cell lymphoma (DLBCL), and you plan to get CAR T at Moffitt.
- You are age 18 or older, can understand the study, and agree to sign consent forms.
- You must be eligible for CAR T using axicabtagene ciloleucel (including the approved lymphoma types).
- Your blood tests at screening must show ferritin above 400 mg/mL and C-reactive protein above 2 mg/dL (20 mg/L).
- Your general health must be in the ECOG 0 to 2 range (a measure of how active you are).
- You cannot have certain recent treatments, infections, major heart problems/unstable rhythms, or certain immune system or medication issues.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new CAR-T cell treatment for people with B-cell lymphoma that has come back or not responded to standard treatments. CAR-T cells are specially engineered immune cells that target and kill lymphoma cells. The study aims to see if this treatment is safe and effective.
This trial tests a new two-step treatment: first a small dose of radiation (131I-Apamistamab) followed by specially designed immune cells (CAR-T cells) to fight your lymphoma. It is for people with DLBCL that has relapsed or not responded to standard therapy.
This Phase 2 study tests whether adding or switching drug treatments after CAR T-cell therapy can improve outcomes for people with certain aggressive lymphomas that have come back or did not respond. It mainly looks at who remains disease-stable/partly improved after CAR T and what treatment approach works best next.
This trial tests a special immune cell therapy (CAR-T cells) for people with a type of aggressive lymphoma that returned more than a year after first treatment. It aims to see if this therapy can help control the cancer again.
This trial tests if giving radiation to all visible tumor sites before standard CAR T-cell therapy can improve outcomes for people with high-risk large B-cell lymphoma. You may be eligible if you have at least one large tumor (5 cm or bigger) that can be targeted with radiation.
This trial tests a combination of two drugs, tafasitamab and lenalidomide, as a first follow-up treatment for people with large B-cell lymphoma that did not fully go away after CAR-T therapy. The goal is to see if this drug pair can help shrink or control the remaining cancer.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.